Mostrar el registro sencillo del ítem
dc.contributor.author | González Valdivieso, Juan | |
dc.contributor.author | Girotti ., Alessandra | |
dc.contributor.author | Schneider, Jose | |
dc.contributor.author | Arias Vallejo, Francisco Javier | |
dc.date.accessioned | 2025-01-16T11:33:43Z | |
dc.date.available | 2025-01-16T11:33:43Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | International Journal of Pharmaceutics, April 2021, vol. 599, 120438 | es |
dc.identifier.issn | 0378-5173 | es |
dc.identifier.uri | https://uvadoc.uva.es/handle/10324/73938 | |
dc.description | Producción Científica | es |
dc.description.abstract | Cancer has reached pandemic dimensions in the whole world. Although current medicine offers multiple treatment options against cancer, novel therapeutic strategies are needed due to the low specificity of chemotherapeutic drugs, undesired side effects and the presence of different incurable types of cancer. Among these new strategies, nanomedicine arises as an encouraging approach towards personalized medicine with high potential for present and future cancer patients. Therefore, nanomedicine aims to develop novel tools with wide potential in cancer treatment, imaging or even theranostic purposes. Even though numerous preclinical studies have been published with successful preliminary results, promising nanosystems have to face multiple obstacles before adoption in clinical practice as safe options for patients with cancer. In this MiniReview, we provide a short overview on the latest advances in current nanomedicine approaches, challenges and promising strategies towards more accurate cancer treatment. | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.classification | Cancer | es |
dc.subject.classification | Nanomedicine | es |
dc.subject.classification | Chemotherapy | es |
dc.subject.classification | Drug delivery | es |
dc.subject.classification | Nanodrugs | es |
dc.title | Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation | es |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.holder | © 2021 Elsevier | es |
dc.identifier.doi | 10.1016/j.ijpharm.2021.120438 | es |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S0378517321002428 | es |
dc.identifier.publicationfirstpage | 120438 | es |
dc.identifier.publicationtitle | International Journal of Pharmaceutics | es |
dc.identifier.publicationvolume | 599 | es |
dc.peerreviewed | SI | es |
dc.description.project | Ministerio de Ciencia, Innovación y Universidades (PID2019-106386RB-I00) | es |
dc.description.project | CIBER-BBN (DTS19/00162) | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.type.hasVersion | info:eu-repo/semantics/submittedVersion | es |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
La licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional